Lovastatin ratiopharm 40 mg Norge - norsk - Statens legemiddelverk

lovastatin ratiopharm 40 mg

ratiopharm gmbh - lovastatin - tablett - 40 mg

Metoclopramide Orifarm 10 mg Norge - norsk - Statens legemiddelverk

metoclopramide orifarm 10 mg

orifarm generics a/s - metoklopramidhydrokloridmonohydrat - tablett - 10 mg

Moxonidin Actavis 0.2 mg Norge - norsk - Statens legemiddelverk

moxonidin actavis 0.2 mg

actavis group ptc ehf (1) - moksonidin - tablett, filmdrasjert - 0.2 mg

Moxonidin Actavis 0.4 mg Norge - norsk - Statens legemiddelverk

moxonidin actavis 0.4 mg

actavis group ptc ehf (1) - moksonidin - tablett, filmdrasjert - 0.4 mg

Metoclopramide Accord 10 mg Norge - norsk - Statens legemiddelverk

metoclopramide accord 10 mg

accord healthcare b.v. - metoklopramidhydrokloridmonohydrat - tablett - 10 mg

Ranitidin ratiopharm 75 mg Norge - norsk - Statens legemiddelverk

ranitidin ratiopharm 75 mg

ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 75 mg

Truxal 15 mg Norge - norsk - Statens legemiddelverk

truxal 15 mg

h. lundbeck a/s - klorprotiksenhydroklorid - tablett, filmdrasjert - 15 mg

Truxal 25 mg Norge - norsk - Statens legemiddelverk

truxal 25 mg

h. lundbeck a/s - klorprotiksenhydroklorid - tablett, filmdrasjert - 25 mg

Truxal 50 mg Norge - norsk - Statens legemiddelverk

truxal 50 mg

h. lundbeck a/s - klorprotiksenhydroklorid - tablett, filmdrasjert - 50 mg

Carmustine medac (previously Carmustine Obvius) Den Europæiske Union - norsk - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastiske midler - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).